Skip to main content
Guide 01/01

First section

Next: Next section

Quick jumps

Fibromyalgia, brain fog and what helps

Can fibromyalgia cause brain fog?

Yes. Fibromyalgia can affect memory, attention and how long you can keep thinking clearly. People call it fibro fog. Some people get substantial pain relief, but research is less clear on whether memory recovers. There are treatments to consider, missed causes to investigate and ways to make daily life easier.

See 40 treatment and support options
Adult guideEditorial update: 19 September 2026Research and sources

The 2026 genetics study

Fibromyalgia just got the biological evidence people have waited decades for.

Not 40 patients. Not another tiny brain scan.

2,563,755 people.

Including 54,629 people with fibromyalgia. Researchers compared their DNA with that of people without the diagnosis and found 26 associated genetic regions.

If people have told you for years that nothing is wrong because your routine tests look normal, this study is worth knowing about. It gives researchers specific genes and nerve-cell types to investigate.

The genetics helps explain the biology of fibromyalgia. To understand the memory problems themselves, we also need studies that test memory and attention.

What does fibro fog feel like?

People often call it fibro fog when they forget the next step in a familiar activity. You may forget an instruction before you finish it, take longer to answer a question, or lose your place after an interruption. Some people also notice sensitivity to light or sound.

In a study comparing 57 people with fibromyalgia with 57 people who had other rheumatic conditions, 70% reported memory decline, compared with 25%. And 56% reported mental confusion, compared with 12%. People described their own symptoms. The study didn't diagnose a memory disorder. (65)

What research shows about fibromyalgia brain fog

People with fibromyalgia scored lower, on average, on tests of attention and verbal working memory. Working memory is how you keep information in mind while using it, such as remembering the beginning of a paragraph as you read the end. These group results cannot tell you how much your own memory has changed. (68) · (131)

Interruptions made new material harder to remember

In a 2009 study, people with fibromyalgia had particular difficulty remembering new material after an interruption. They could still recall well-rehearsed material. These people had sought help for memory problems, so the results may not apply to everyone with fibromyalgia. (66)

Similar word-task scores, but more pain and physical fatigue

During an 18-minute word-generation task, people with fibromyalgia produced similar word totals to the comparison group. Their pain and physical fatigue increased more during the task. (67)

Study details: memory, attention and fatigue

A confidence interval shows uncertainty around the study’s estimate. It is not the range of results each patient should expect or the chance that treatment will help one person.

The 2025 review combined 29 studies. The average difference in verbal working memory was moderate (Hedges’ g −0.66; 95% confidence interval −0.94 to −0.38). The overall visual working-memory result was not statistically different, although a women-only analysis found differences in both verbal and visual working memory. (68)

The 2018 review combined 37 studies, with 964 participants with fibromyalgia and 1,025 controls. The largest group difference was in inhibitory control: ignoring a distraction or holding back an irrelevant response during a task. The review also found differences in memory, processing speed and executive function, which includes planning and organizing tasks. (69)

The 18-minute word-generation study compared 24 people with fibromyalgia and 33 controls. The difference in mental fatigue did not reach statistical significance, even though pain and physical fatigue increased more in the fibromyalgia group. (67)

Try the free brain-fog memory games. These are practice activities. Notice whether you can finish, whether errors increase, and how the effort feels.

Why is thinking harder on some days?

Thinking may be worse when you have slept badly, pain flares, or noise keeps interrupting you. Ask about side effects if the change began after starting or changing a medicine. The related-causes guide below explains which details matter.

What did the genetics study find in the brain?

The genetic links to fibromyalgia clustered in brain tissue. Of 53 tissue types examined, all five with statistically significant findings were brain regions. (71)

Which nerve cells were involved?

A second analysis used an atlas of mouse cell types to help interpret the human genetic findings. Of the 13 cell types linked to the findings, 12 were nerve cells. The strongest link involved nerve cells in the dentate gyrus, part of the hippocampus.

Researchers checked where genes near the associated genetic regions were especially active. They adjusted the statistical tests for the many comparisons, which can otherwise produce chance findings. Related cell types have similar patterns of gene activity, so the study could not easily identify one responsible cell type. Most people with fibromyalgia in the study were women of European ancestry. The study did not test memory. Full study and methods

Does central sensitization explain fibro fog?

Central sensitization means pain pathways respond more strongly. It helps explain increased pain sensitivity; its role in memory problems is less clear. (70)

What did the symptom and memory tests find?

The Central Sensitization Inventory (CSI) asks about symptoms. In a 2026 study of 120 women, those with higher CSI scores reported more thinking difficulties. After researchers accounted for other factors, they found no clear link between CSI scores and results on the MoCA thinking test. The questionnaire does not directly test pain pathways. Yücel and Kurt, 2026

What do brain-wave recordings show?

People with fibromyalgia tended to have less slow-wave activity and more fast beta-wave activity than healthy comparison groups. (132)

What can't the brain-wave findings (EEG) tell us?

The review covered fibromyalgia, ME/CFS and Long COVID. Samples and methods varied. It compared groups. It gave no test that tells these conditions apart, or spots brain fog, in one person.

Early treatment research

Could the genetics study lead to new fibromyalgia treatments?

Two genes the study highlighted are already the focus of treatment research for other conditions. The fibromyalgia findings give researchers a reason to test whether those approaches could help here.

GPR52: a drug target being studied for Huntington’s disease

One of the genetic regions associated with fibromyalgia lies near GPR52, a gene that encodes a receptor particularly active in the brain. That receptor regulates levels of the huntingtin protein. GPR52 is already a drug target in Huntington's disease research, so the fibromyalgia authors suggest testing whether drugs developed for that target could help fibromyalgia.

CELF4: a possible way to alter pain sensitivity

Another genetic association was near CELF4, which helps control how easily pain-sensing nerve cells fire. Researchers are already studying CELF4-based gene therapy for chronic pain. The authors argue these genetic findings give a reason to explore it in fibromyalgia.

GPR52 and CELF4 are research targets, not available fibromyalgia treatments. Separately, a Duke magnetic-stimulation pilot is measuring cognition, fatigue and pain. See current trials and what they measure.

For the parent wondering what “genetic” means

Will my children get fibromyalgia too?

Having fibromyalgia does not mean your children will develop it. The study found many inherited differences that each contribute to risk. It didn't find one gene that decides who gets the illness.

In European-ancestry participants, fibromyalgia prevalence ranged from about 1.0% in the lowest genetic-risk fifth to 2.4% in the highest. Even in that highest group, most people did not have the diagnosis.

Those are population numbers, not your son's or daughter's own odds.

What do the heritability and risk-score numbers mean?

Common genetic variants accounted for about 10.4% of the observed variation in fibromyalgia status. That's a population estimate, not how much of one person's illness is genetic. The combined genetic-risk score had an AUC of 0.59 in European-ancestry participants. On this measure, 0.5 is chance and 1 is perfect separation of cases from controls, so the score was a weak predictor.

Did the genetics study find brain damage?

The genetic findings don't show that brain tissue is being destroyed. The study did not scan people for lesions, tissue loss or progressive degeneration.

The strongest association involved HTT, a gene also involved in Huntington’s disease. The fibromyalgia variant lies in a different part of the gene from the repeat expansion that causes Huntington’s. Sharing a gene name does not make the two conditions the same disease.

Fibromyalgia genetics: immunity, PTSD, sex differences and the gut

Do the genetic findings suggest fibromyalgia is autoimmune?

The 2026 genetics study favoured a nervous-system explanation over a mainly autoimmune one. Immune activity outside the brain and how immune cells interact with nerves remain open questions.

Genetic overlap with PTSD and IBS

Fibromyalgia showed strong genetic overlap with chronic pain, PTSD and IBS, so they share some inherited risk.

Similar genetic findings in men and women

Men and women had nearly identical genetic findings, even though doctors diagnose far more women. Other biological differences, environment and differences in diagnosis could explain that gap.

The study also implicated nerve cells in the gut

Nerve cells in the gut were also linked to the genetic findings. Together with the overlap with IBS, this makes gut nerve function another area to investigate.

The history of fibromyalgia and brain fog

  1. 1904

    Gowers calls it “fibrositis”

    William Gowers introduced “fibrositis” for complaints then often called muscular rheumatism. The name suggested inflammation of fibrous muscle tissue. “Fibromyalgia” followed in 1976. The changing names show how doctors revised their ideas about the illness. Inanici and Yunus’s history review · The earlier inflammation theory

  2. 1975

    An experiment connects disrupted sleep with pain

    Moldofsky and colleagues interrupted deep sleep in healthy volunteers. Temporary muscle and joint symptoms and mood changes accompanied the disruption. The researchers also observed alpha activity during non-REM sleep in patients with “fibrositis” and in the volunteers, a finding called alpha-delta sleep. The experiment showed that disrupted sleep can accompany pain and other symptoms; it did not establish one cause for every case. Original sleep experiment

  3. 1990

    Tender points standardize research

    The American College of Rheumatology’s classification criteria combined widespread pain with tenderness at 11 or more of 18 specified sites. Researchers now had a shared way to classify participants. Cognitive difficulty was not part of that rule. 1990 criteria

  4. 2010

    Cognitive symptoms enter the diagnostic criteria

    New preliminary diagnostic criteria included cognitive symptoms alongside fatigue and waking unrefreshed. They used a pain index and symptom-severity scale without requiring the tender-point examination. Memory and thinking were now part of the formal assessment. 2010 criteria

  5. 2014

    A clinical review explains altered pain processing

    Clauw’s JAMA review described fibromyalgia as the brain and spinal cord processing pain and sensation differently. That could explain widespread sensitivity without an injury at every painful site. Clauw’s clinical review

  6. 2015

    Researchers develop the MISCI questionnaire

    Researchers developed the ten-item MISCI using responses from 1,035 adults with fibromyalgia, then evaluated it in another 232. It gave researchers a brief way to follow changes in the cognitive difficulties people reported, instead of relying on a much longer questionnaire. MISCI development study

  7. 2017

    Treatment recommendations favor exercise

    Exercise received the only strong recommendation for a therapy in EULAR’s revised guidance. The main outcomes considered were pain, fatigue, sleep and daily functioning. That recommendation was not a finding that exercise repairs memory. EULAR recommendations

  8. 2017–2021

    “Nociplastic” names another way pain can arise

    IASP adopted the term in 2017; a 2021 Lancet review examined it with fibromyalgia as a major example. Nociplastic pain refers to altered pain processing when tissue damage or a disease or injury of sensory nerves does not adequately explain the pain. It can also coexist with pain from tissue damage or nerve injury. IASP chronology · 2021 review

  9. 2025

    Researchers question what “brain fog” includes

    Denno and colleagues compared the term across medical conditions. They found overlapping complaints involving cognition, fatigue and mood, and argued that similar language and cognitive difficulties need not mean a shared biological cause. People can use the same phrase for different causes, so research has to separate them. Defining brain fog across conditions

How is fibromyalgia diagnosed when tests are normal?

You can have fibromyalgia and normal blood tests. Doctors diagnose it from where you hurt, how long it has lasted, your other symptoms and an examination. Blood tests help check for other illnesses. ACR overview

The symptoms must have lasted at least three months. Fibromyalgia can also be diagnosed alongside another illness. (74)

Which diagnostic criteria do doctors use?

The 2016 criteria require pain in at least four of five body regions, symptoms for at least three months, and a combination of pain and symptom-severity scores.

Doctors look for a Widespread Pain Index (WPI) of at least 7 with a Symptom Severity (SS) score of at least 5, or WPI 4 to 6 with SS of at least 9. The four-region rule helps separate widespread symptoms from pain in one area. Your doctor uses your history and exam alongside these criteria.

How common is fibromyalgia, and can children have it?

The American College of Rheumatology estimates that fibromyalgia affects 2% to 4% of people. Children and teenagers can have juvenile fibromyalgia. A pediatric assessment should consider school, sleep and daily activities. The treatment information on this page is for adults. ACR overview · Pain in children and teenagers

Is memory loss with fibromyalgia a sign of dementia?

Not by itself. Research more often finds problems with working memory, attention and processing speed than the progressive loss of familiar knowledge associated with dementia. Fibro fog does not rule dementia in or out. Get new or steadily worsening changes checked separately from fibromyalgia, especially if someone gets lost in familiar places, can't manage usual bills or medicines, gets confused about time or people, or isn't safe doing familiar activities anymore. (99)

What should be checked when fibromyalgia treatment isn’t helping?

Start with sleep problems and medicine side effects. Bring earlier results so you can check which tests you've already had. (75)

Which sleep problem needs treatment?

Trouble falling or staying asleep: ask about insomnia treatment. CBT for insomnia (CBT-I) improved sleep in a review of 47 trials. CBT aimed at pain did not show the same sleep benefit. Pathak, 2025

Snoring, gasping or pauses in breathing: ask about sleep apnea. If a home test is negative, unclear or fails to record usable data, and sleep apnea is still suspected, AASM recommends a laboratory sleep study. Severe insomnia may call for laboratory testing from the start. (148)

An urge to move your legs at night: restless legs typically gets worse at rest and eases with movement. Describe that urge, including when it happens. (149)

When do iron results affect restless-legs treatment?

For clinically significant restless legs, the 2025 AASM guideline advises checking ferritin and transferrin saturation. Its expert-consensus thresholds are ferritin 75 ng/mL or less, or transferrin saturation below 20%. These differ from the thresholds commonly used for anemia. You need more than a result below them to start iron. AASM restless-legs guideline

Study details: sleep treatments

A 2025 evidence synthesis found 168 fibromyalgia sleep-treatment studies. Its sleep-quality network analysis included 65 studies and 8,247 participants, but evidence for individual treatments was often low-certainty. The separate 47-trial drug and CBT review looked at sleep, not memory recovery. Sleep-treatment review · Drug and CBT review

Can a medicine cause brain fog even if the dose hasn’t changed?

Yes. Pregabalin leaves your body mainly through the kidneys. Reduced kidney function or adding another sedating medicine can increase side effects, even at the same dose. Include sleep aids and antihistamines in a medicine review. (79)

Which blood tests might help?

Tests depend on your symptoms and earlier results. Our guides explain blood count, thyroid function, CRP (inflammation), B12 and ferritin (iron stores). (150) · Brain fog with normal blood work

When symptoms change during pregnancy, after birth or at menopause

Describe when your thinking changed, including any sleep disruption, hot flashes, heavy bleeding or medicine changes. These details can help decide whether to check thyroid function, anemia, sleep or mood.

What do pregnancy and menopause studies tell us?

Pregnancy studies are limited and have mainly measured pain, mood and pregnancy outcomes. A review of menopause and fibromyalgia also found too little evidence to establish one hormonal explanation or a specific treatment for fibromyalgia symptoms. (106) · (107)

Burning or numbness, or feeling faint when standing

Burning pain, numbness or changes in temperature sensation can warrant a nerve assessment. Feeling faint or having a racing heart when standing needs a separate check. (151)

Why do small-nerve-fiber studies give different results?

A 2019 review combined studies of small skin samples, called biopsies. It estimated that 45% of adults studied with fibromyalgia had abnormal findings; the 95% confidence interval was 32% to 59%. In a 2025 study of 46 women, only one met that study’s criteria for small-fiber neuropathy, a disorder of the small nerves. Many still reported nerve-related symptoms. The studies examined different groups and used different definitions. An abnormal skin sample and a neuropathy diagnosis are different results. Neither study identified the cause of brain fog. (80) · (152)

Depression and anxiety deserve their own assessment when their symptoms are present.

Is it fibro fog or ADHD?

Forgetfulness and trouble concentrating can look similar, but an ADHD assessment looks for a history that began in childhood. For an adult diagnosis, symptoms must have started before age 12 and interfere with more than one part of life.

That doesn't mean you needed a childhood diagnosis. School reports and recollections from people who knew you then can help establish the history. Difficulties may only become obvious when adult responsibilities increase.

Compare longstanding problems with a change that began around illness, disrupted sleep or a medicine change. NIMH adult ADHD guidance · ADHD and brain fog

How can I explain brain fog at an appointment?

Bring your medicine list and one example of how brain fog affects your day. Explain whether it changes with pain, sleep or treatment.

“My pain is better, but I still lose track of conversations. Could poor sleep or my medicine be adding to the brain fog?”

Suggested wording to adapt.

Open the doctor handout

Includes appointment questions and care information for the US, UK and Australia.

Optional: record cognitive symptoms with the MISCI-derived questions

Cognitive symptom record

Questions about memory and concentration (MISCI-derived)

We adapted questions from the validated MISCI questionnaire, which records memory and concentration symptoms in fibromyalgia. This page saves your answers. It does not calculate the official MISCI score or diagnose a condition.

Rate each statement for the past 7 days.

1. My mind has been as sharp as usual
2. I have been able to concentrate
3. I have been able to think clearly
4. My memory has been as good as usual
5. My thinking has been slow
6. I have had trouble forming thoughts
7. I have had trouble finding the right word(s)
8. I have had trouble remembering things
9. I have had trouble shifting between tasks
10. I have had difficulty making decisions
Optional: record other symptoms with the Central Sensitization Inventory

Symptom inventory

Central Sensitization Inventory, Part A

Rate each of the 25 statements using the response that fits best. You can also use the original printable form.

1. I feel tired and unrefreshed when I wake from sleeping
2. My muscles feel stiff and achy
3. I have anxiety attacks
4. I grind or clench my teeth
5. I have problems with diarrhea and/or constipation
6. I need help in performing my daily activities
7. I am sensitive to bright lights
8. I get tired very easily when I am physically active
9. I feel pain all over my body
10. I have headaches
11. I feel discomfort in my bladder and/or burning when I urinate
12. I do not sleep well
13. I have difficulty concentrating
14. I have skin problems such as dryness, itchiness, or rashes
15. Stress makes my physical symptoms get worse
16. I feel sad or depressed
17. I have low energy
18. I have muscle tension in my neck and shoulders
19. I have pain in my jaw
20. Certain smells, such as perfumes, make me feel dizzy and nauseated
21. I have to urinate frequently
22. My legs feel uncomfortable and restless when I am trying to go to sleep at night
23. I have difficulty remembering things
24. I suffered trauma as a child
25. I have pain in my pelvic area

Research and sources

Community experiences can reveal practical problems, but they are not clinical evidence.

References

  1. Macfarlane et al. EULAR revised recommendations for fibromyalgia (online 2016; journal issue 2017). DOI: 10.1136/annrheumdis-2016-209724.

    Indexed guideline abstract; evidence search ended May 2015.

  2. NICE NG193. Chronic primary pain: recommendations (7 April 2021), especially sections 1.2.1–1.2.11.

    Official guideline; relevant recommendation text retrieved through indexed search.

  3. NICE NG206. ME/CFS: diagnosis and management (2021), especially section 1.11 on physical activity and exercise.

    Official guideline; applies to ME/CFS, not automatically to everyone with fibromyalgia.

  4. NIAMS. Fibromyalgia: diagnosis, treatment, and steps to take.

    Official patient information; practical guidance, not a treatment trial.

  5. NHS. Fibromyalgia: self-help.

    Official patient information.

  6. Queen Elizabeth Hospital King’s Lynn. Pain-management occupational therapy.

    NHS service information; describes adaptations and occupational therapy, not quantified efficacy.

  7. UCLH. Chronic fatigue syndrome and fibromyalgia service.

    NHS clinical-service information; assessment, medication review and multidisciplinary support.

  8. Kengen Traska et al. Strategies used for managing symptoms by women with fibromyalgia (online 2011; journal issue 2012). DOI: 10.1111/j.1365-2702.2010.03501.x.

    This was an interview study of eight women's experiences.

  9. NINDS. Restless legs syndrome.

    Official clinical information about a separate, potentially coexisting condition.

  10. NIDDK. Eating, diet, and nutrition for coeliac disease; reviewed October 2020.

    Official patient information; includes testing before removing gluten.

  11. Bidonde et al. Aerobic exercise for adults with fibromyalgia. Cochrane (2017). DOI: 10.1002/14651858.CD012700.

    Systematic-review summary and quantitative results.

  12. Bidonde et al. Aquatic exercise training for fibromyalgia. Cochrane (2014). DOI: 10.1002/14651858.CD011336.

    Systematic-review summary and quantitative results.

  13. Larsson et al. Person-centred resistance exercise in women with fibromyalgia (2015). DOI: 10.1186/s13075-015-0679-1.

    Randomized trial; indexed abstract.

  14. Wang et al. Tai chi compared with aerobic exercise for fibromyalgia. BMJ (2018). DOI: 10.1136/bmj.k851.

    Randomized comparative-effectiveness trial; publisher text.

  15. Carson et al. Yoga of Awareness pilot trial in fibromyalgia (2010). DOI: 10.1016/j.pain.2010.08.020.

    Randomized trial; indexed abstract.

  16. Lynch et al. Qigong for fibromyalgia: randomised controlled trial (2012). DOI: 10.1186/ar3931.

    Randomized trial; indexed abstract. This is not itself a systematic review.

  17. Dailey et al. TENS for movement-evoked pain and fatigue. Arthritis & Rheumatology (2020). DOI: 10.1002/art.41170.

    Randomized active/placebo/no-TENS trial; publisher abstract and relevant full-text passages.

  18. Dailey et al. FM-TIPS: TENS added to physical therapy. JAMA Network Open (27 March 2026). DOI: 10.1001/jamanetworkopen.2026.2450.

    Cluster-randomized trial; publisher HTML. The journal corrected Tables 1 and 2 on 27 April 2026, so use its updated version.

  19. NHS. Transcutaneous electrical nerve stimulation: use and safety.

    Official device-safety information.

  20. Castro-Sánchez et al. Massage–myofascial release in fibromyalgia (2011). DOI: 10.1155/2011/561753.

    Randomized trial; indexed abstract.

  21. Vas et al. Individualised acupuncture for fibromyalgia (2016). DOI: 10.1136/acupmed-2015-010950.

    Sham-controlled randomized trial; publisher abstract.

  22. Fioravanti et al. Balneotherapy for primary fibromyalgia (2018). DOI: 10.1007/s10067-018-4117-z.

    Mineral-water versus tap-water randomized trial; indexed abstract.

  23. McCrae et al. SPIN trial: CBT for insomnia and pain (2019). DOI: 10.1093/sleep/zsy234.

    Randomized trial; indexed abstract. Primary average outcomes and responder analyses distinguished.

  24. Moore et al. Overview of Cochrane reviews of fibromyalgia medicines (online 2024; journal issue 2025). DOI: 10.1093/rheumatology/keae707.

    Overview of systematic reviews; indexed abstract. Search ended May 2024, so it predates several newer studies below.

  25. Cochrane. Duloxetine for neuropathy, chronic pain or fibromyalgia (2014). DOI: 10.1002/14651858.CD007115.pub3.

    Systematic review; fibromyalgia subgroup kept separate from other conditions.

  26. MedlinePlus. Duloxetine: medicine information.

    Official medicine information; safety, interactions and withdrawal.

  27. Cochrane. Milnacipran for fibromyalgia in adults (2015). DOI: 10.1002/14651858.CD008244.pub3.

    Systematic-review summary.

  28. MedlinePlus. Milnacipran: medicine information.

    Official medicine information; safety, interactions and withdrawal.

  29. Cochrane. Pregabalin for fibromyalgia pain in adults (2016).

    Systematic-review summary; conventional and enriched-enrolment designs distinguished.

  30. NHS. Who can and cannot take pregabalin.

    Official medicine-safety information.

  31. Cochrane. Amitriptyline for fibromyalgia in adults (2015). DOI: 10.1002/14651858.CD011824.

    Systematic-review summary; very-low-certainty efficacy evidence.

  32. NHS. Side effects of amitriptyline for pain and migraine.

    Official medicine-safety information.

  33. DailyMed. Tonmya (sublingual cyclobenzaprine) US prescribing information; updated 24 June 2026.

    Official label text; adult indication, contraindications, oral adverse effects and pregnancy precautions.

  34. RESILIENT phase 3 trial of bedtime sublingual cyclobenzaprine (published online 2025). PMID: 40627411.

    Randomized trial; indexed abstract.

  35. RELIEF phase 3 trial of bedtime sublingual cyclobenzaprine (2023). PMID: 37165930.

    Randomized trial; indexed abstract.

  36. Al-Qudah et al. Meta-analysis of sublingual cyclobenzaprine trials (online 2025; journal issue 2026). DOI: 10.1007/s10067-025-07863-5.

    Systematic review/meta-analysis; indexed abstract.

  37. Cochrane. Cognitive behavioural therapies for fibromyalgia (2013). DOI: 10.1002/14651858.CD009796.pub2.

    Systematic-review summary; low-certainty evidence.

  38. Gendreau et al. PROSPER-FM: digital ACT versus symptom tracking and education. Lancet (2024). DOI: 10.1016/S0140-6736(24)00909-7.

    Randomized trial; indexed abstract. Funded by Swing Therapeutics.

  39. Pérez-Aranda et al. EUDAIMON mindfulness trial (2019). DOI: 10.1097/j.pain.0000000000001655.

    Three-arm randomized trial; indexed abstract.

  40. Lumley et al. Emotional awareness and expression therapy in fibromyalgia (2017). DOI: 10.1097/j.pain.0000000000001036.

    Cluster-randomized trial; indexed abstract. Primary and secondary outcomes distinguished.

  41. Placebo-controlled vitamin D trial in fibromyalgia (2021). DOI: 10.1007/s10067-021-05640-8.

    Randomized trial; indexed abstract.

  42. Silva et al. Combined dietary intervention including a low-FODMAP phase (2022). DOI: 10.3389/fnut.2022.856216.

    Randomized trial; indexed abstract. Multiple dietary components changed together.

  43. Casini et al. Personalised Mediterranean-style diet in fibromyalgia (2024). DOI: 10.1007/s40122-024-00598-2.

    Controlled study; indexed abstract and available figure description. Not classified here as securely randomized.

  44. de Zanette et al. Melatonin, amitriptyline and their combination (2014). DOI: 10.1186/2050-6511-15-40.

    Randomized active-comparator trial; indexed abstract. No inert-placebo-only arm.

  45. Macian et al. Magnesium supplementation in fibromyalgia (2022). DOI: 10.3390/nu14102088.

    Placebo-controlled trial; indexed abstract. Negative overall primary outcome; exploratory subgroup finding.

  46. Sawaddiruk et al. CoQ10 added to pregabalin (2019). DOI: 10.1080/10715762.2019.1645955.

    Small randomized crossover trial; indexed abstract.

  47. NCCIH. Coenzyme Q10: safety and interactions.

    Official supplement-safety information; not fibromyalgia efficacy evidence.

  48. Chaves et al. THC-rich cannabis oil for fibromyalgia (2020). DOI: 10.1093/pm/pnaa303.

    Small placebo-controlled randomized trial; indexed abstract.

  49. Kurlyandchik et al. THC:CBD oil feasibility pilot (2026). DOI: 10.1155/prm/7311235.

    Randomized feasibility trial; publisher abstract. Efficacy outcomes were secondary and preliminary.

  50. Rasmussen et al. CBD versus placebo for fibromyalgia (online 2025; journal issue March 2026). DOI: 10.1016/j.ard.2025.07.008.

    Randomized trial; indexed abstract. Placebo produced greater pain improvement.

  51. NCCIH. Cannabis and cannabinoids: evidence and safety.

    Official safety information; general cannabinoid risks are not fibromyalgia-specific event rates.

  52. Younger et al. Low-dose naltrexone crossover trial (2013). DOI: 10.1002/art.37734.

    Small randomized crossover trial; publisher abstract.

  53. Due Bruun et al. FINAL: naltrexone versus placebo (2024). DOI: 10.1016/S2665-9913(23)00278-3.

    Randomized trial; indexed abstract.

  54. Rodríguez-Freire et al. INNOVA: 12-month naltrexone trial (2026). DOI: 10.1002/ejp.70321.

    Publisher abstract and full-text passages retrieved through indexed search; direct opening was intermittent.

  55. Systematic review/meta-analysis of low-dose naltrexone trials (2024). PMCID: PMC11450306.

    Systematic review; four trials, 222 participants. Predates INNOVA.

  56. MedlinePlus. Naltrexone: medicine information.

    Official medicine information; opioid antagonism, withdrawal risk and other precautions.

  57. Boyer et al. rTMS, quality of life and brain metabolism (2014). DOI: 10.1212/WNL.0000000000000280.

    Sham-controlled trial; indexed abstract. No significant pain benefit in this particular study.

  58. da Mota Neto et al. HOTFy: hyperbaric oxygen trial (2026). DOI: 10.1136/bmjopen-2025-112284.

    Randomized early-versus-delayed treatment trial; indexed abstract. No sham chamber.

  59. Navarro-Ledesma et al. Whole-body photobiomodulation (online 2022; journal issue 2023). DOI: 10.1007/s40122-022-00450-5.

    Small sham-controlled trial; indexed abstract; device-company affiliations disclosed.

  60. Noppers et al. Short S-ketamine infusion in fibromyalgia (2011). DOI: 10.1016/j.ejpain.2011.03.008.

    Small active-placebo-controlled trial; publisher abstract.

  61. NIH Office of Dietary Supplements. Magnesium: health professional fact sheet.

    Official supplement-safety information.

  62. NCCIH. Melatonin: evidence, safety and product quality.

    Official information; chronic insomnia and circadian timing disorders distinguished.

  63. NIDDK. Eating, diet, and nutrition for irritable bowel syndrome.

    Official dietary guidance; time-limited low-FODMAP trial with reintroduction.

  64. NHS. Fibromyalgia: treatment.

    Official patient information; multimodal care and treatment options.

  65. Katz et al. (2004). Self-reported cognitive symptoms in fibromyalgia.
  66. Leavitt and Katz (2009). Distraction and memory in a selected clinical sample.
  67. Dailey et al. (2015). Pain and fatigue during a cognitive task.
  68. Nicholls and Kelly (2025). Working-memory systematic review and meta-analysis.
  69. Bell et al. (2018). Meta-analysis of cognitive performance.
  70. Woolf (2011). Central sensitization and pain.
  71. Kerrebijn et al. (2026). Fibromyalgia genome-wide association study.
  72. Yücel and Kurt (2026). CSI, symptoms and cognitive screening in 120 women.
  73. Wolfe et al. (2010). Diagnostic criteria including cognitive symptoms.
  74. Wolfe et al. (2016). Revised diagnostic criteria.
  75. HAS (2025). Fibromyalgia diagnosis and treatment guideline.
  76. AASM (2017). Diagnostic testing for obstructive sleep apnea.
  77. NINDS. Restless legs syndrome.
  78. AASM (2025). Restless legs and periodic limb movement disorder guideline.
  79. Pregabalin prescribing information. Adverse effects, renal dosing and withdrawal.
  80. Grayston et al. (2019). Meta-analysis of small-fiber pathology.
  81. Bay-Smidt et al. (2025). Small-fiber and autonomic assessment in 46 women.
  82. NICE NG206. ME/CFS and post-exertional malaise.
  83. Bidonde et al. (2017). Cochrane review of aerobic exercise.
  84. Kazemipour et al. (2025). CBT and cognitive outcomes.
  85. Pain neuroscience education trial (2026). Cognitive outcomes in 62 women.
  86. Rodríguez-Freire et al. (2026). INNOVA low-dose naltrexone trial.
  87. Lederman et al. (2026). Sublingual cyclobenzaprine trial.
  88. FDA (2025). Tonmya approval letter.
  89. Inanici and Yunus (2004). History of fibromyalgia.
  90. Moldofsky et al. (1975). Deep-sleep disruption experiment.
  91. Wolfe et al. (1990). Classification criteria.
  92. Clauw (2014). Fibromyalgia clinical review.
  93. Kratz et al. (2015). MISCI development.
  94. Macfarlane et al. (2017). EULAR recommendations.
  95. Fitzcharles et al. (2021). Nociplastic pain.
  96. Denno et al. (2025). Defining brain fog across medical conditions.
  97. AFSA. Duke TMS pilot project description; not efficacy results.
  98. Silva-Passadouro et al. (2024). Systematic review of quantitative EEG findings.
  99. National Institute on Aging. Memory problems, forgetfulness and aging.
  100. Lowry et al. (2020). Dietary interventions in fibromyalgia: systematic review and best-evidence synthesis.
  101. Job Accommodation Network (2026). Fibromyalgia accommodation ideas and examples.
  102. EEOC. Work at home or telework as a reasonable accommodation.
  103. CDC. Signs and symptoms of stroke.
  104. DailyMed. Amitriptyline hydrochloride prescribing information.
  105. DailyMed. Duloxetine delayed-release prescribing information.
  106. de Carvalho and Skare (2025). Pregnancy and fibromyalgia systematic review.
  107. Dias et al. (2019). Fibromyalgia, sleep disturbance and menopause: literature review.
  108. 988 Suicide & Crisis Lifeline. Call, text or chat 988 in the United States.
  109. CDC. Meningococcal disease symptoms and complications.
  110. MedlinePlus. Infectious arthritis.
  111. MedlinePlus. Breathing difficulty and emergency warning signs.
  112. Walitt et al. (2011). Long-term outcomes in 1,555 people with fibromyalgia.
  113. Casanova-Rodríguez et al. (2026). Resistance-exercise systematic review and meta-analysis.
  114. Rodríguez-Domínguez et al. (2025). Exercise comparisons for pain in women with fibromyalgia.
  115. Imamura et al. (2025). Fibromyalgia sleep-treatment evidence synthesis.
  116. Pathak et al. (2025). Sleep treatments, including CBT for insomnia versus CBT for pain.
  117. FDA. Stanza prescription digital therapeutic authorization.
  118. Lumley et al. (2017). Emotional awareness and expression therapy trial.
  119. FDA. Tonmya prescribing information.
  120. Tonmya. Manufacturer savings terms, checked September 19, 2026.
  121. NIMH. ADHD in adults: childhood history and assessment.
  122. NIAMS. Fibromyalgia treatment and daily activity.
  123. INFORM metformin study. NCT05900466.
  124. UAB psilocybin study. NCT05068791.
  125. Focused-ultrasound study. NCT07226648.
  126. Rozanolixizumab completed study. NCT05643794.
  127. Goebel et al. (2026). Rozanolixizumab randomized trial.
  128. D-cycloserine plus magnetic stimulation randomized trial (2026).
  129. HHS. Questions about research participation.
  130. Read the Nature Medicine study
  131. 2018 review
  132. 2024 review of 17 EEG studies
  133. Nature Medicine genetics paper
  134. See the heritability and risk-score results
  135. Read the HTT finding
  136. Read the full genetics paper
  137. Walitt and colleagues’ long-term study
  138. NICE guidance
  139. NIAMS advice on pacing daily activity
  140. EULAR guidance
  141. Hypermobility rehabilitation
  142. ACR treatment overview
  143. Tonmya clinical trial
  144. Read the FDA prescribing information
  145. Current savings terms
  146. ACR treatment advice
  147. CBT trial
  148. AASM guidance
  149. NINDS description
  150. Diagnostic guideline
  151. Structured assessment study
  152. 2025 study
  153. EEOC guidance